Abstract
Background Imaging biomarkers of progressive MS are needed. Quantitative gradient recalled echo (qGRE) MRI technique allows evaluation of tissue damage associated with microstructural damage in multiple sclerosis (MS).
Objective To evaluate qGRE-derived R2t* as an imaging biomarker of MS disease progression as compared to atrophy and lesion burden.
Methods Twenty-three non-relapsing progressive MS (PMS), twenty-two relapsing-remitting MS (RRMS) and eighteen healthy control participants were imaged with qGRE at 3T. PMS subjects were imaged and neurologically assessed every nine months over five sessions. In each imaging session, lesion burden, atrophy and R2t* in cortical grey matter (GM), deep GM, normal-appearing white matter (NAWM) were measured.
Results R2t* reductions correlated with neurological impairment cross-sectionally and longitudinally. PMS patients with clinically defined disease progression showed significantly faster decrease of R2t* in NAWM and deep GM compared with the clinically stable PMS group. Importantly, tissue damage measured by R2t* outperformed lesion burden and atrophy as a biomarker of progression during the study period.
Conclusion Clinical impairment and progression correlated with accumulating R2t*-defined microstructural tissue damage in deep GM and NAWM. qGRE-derived R2t* is a potential imaging biomarker of MS progression.
Competing Interest Statement
Anne H. Cross is funded by the Manny & Rosenthal Dr. John L. Trotter MS Center Chair of Barnes Jewish Hospital foundation and the Leon and Harriet Felman Fund for Human MS Research. She has also received consulting and/or speaking fees from Biogen, Celgene, EMD Serono, Genentech/Roche, Greenwich Biosciences, Janssen Pharmaceuticals, Novartis, and Race to Erase MS, all outside the submitted work.
Funding Statement
This work was supported by Marilyn Hilton Award for Innovation in MS from the Conrad N. Hilton Foundation; the National MS Society USA [FG-1908-34882]; NIH/NIA AG054513; 2R25NS090978-06. Anne H. Cross was funded in part by the Manny and Rosalyn Rosenthal-Dr. John L. Trotter MS Center Chair of Barnes-Jewish Hospital Foundation, and the Leon and Harriet Felman Fund for Human MS Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Washington University in St. Louis
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, Anne H. Cross, upon reasonable request.
